Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul:133:144-150.
doi: 10.1016/j.lungcan.2019.05.015. Epub 2019 May 15.

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

Jacqueline V Aredo  1 , Sukhmani K Padda  1 , Christian A Kunder  2 , Summer S Han  1 , Joel W Neal  1 , Joseph B Shrager  1 , Heather A Wakelee  3
Affiliations

Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes

Jacqueline V Aredo et al. Lung Cancer. 2019 Jul.

Abstract

Objectives: Concurrent genetic mutations are prevalent in KRAS-mutant non-small cell lung cancer (NSCLC) and may differentially influence patient outcomes. We sought to characterize the effects of KRAS mutation subtypes and concurrent pathogenic mutations on overall survival (OS) and PD-L1 expression, a predictive biomarker for anti-PD-1/PD-L1 immunotherapy.

Materials and methods: We retrospectively identified patients with KRAS-mutant NSCLC at a single institution and abstracted clinical, molecular, and pathologic data from electronic health records. Cox regression and multinomial logistic regression were used to determine how KRAS mutation subtypes and concurrent pathogenic mutations are associated with OS and tumor PD-L1 expression, respectively.

Results: A total 186 patients were included. Common KRAS mutation subtypes included G12C (35%) and G12D (17%). Concurrent pathogenic mutations were identified in TP53 (39%), STK11 (12%), KEAP1 (8%), and PIK3CA (4%). On multivariable analysis, KRAS G12D mutations were significantly associated with poor OS (hazard ratio [HR] 2.43, 95% confidence interval [CI] 1.15-5.16; P = 0.021), as were STK11 co-mutations (HR 2.95, 95% CI 1.27-6.88; P = 0.012). Compared to no (<1%) PD-L1 expression, KRAS G12C mutations were significantly associated with positive yet low (1-49%) PD-L1 expression (odds ratio [OR] 4.94, 95% CI 1.07-22.85; P = 0.041), and TP53 co-mutations with high (≥50%) PD-L1 expression (OR 6.36, 95% CI 1.84-22.02; P = 0.004).

Conclusion: KRAS G12D and STK11 mutations confer poor prognoses for patients with KRAS-mutant NSCLC. KRAS G12C and TP53 mutations correlate with a biomarker that predicts benefit from immunotherapy. Concurrent mutations may represent distinct subsets of KRAS-mutant NSCLC; further investigation is warranted to elucidate their role in guiding treatment.

Keywords: Concurrent mutation; KRAS; Non-small cell lung cancer; PD-L1; STK11.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Kaplan-Meier survival analysis stratified by KRAS G12D mutation status (a) and STK11 co-mutation status (b). Abbreviations: No. number, WT wildtype, MUT mutant.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR, Rudin CM, Garon EB, Pao W, Schiller JH, Haura EB, Shirai K, Giaccone G, Berry LD, Kugler K, Minna JD, Bunn PA, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC), J. Clin. Oncol. 29 (18_suppl) (2011) CRA7506-CRA7506.
    1. Cancer Genome Atlas Research Network, Comprehensive genomic characterization of squamous cell lung cancers, Nature 489 (7417) (2012) 519–525. - PMC - PubMed
    1. Shepherd FA, Domerg C, Hainaut P, Janne PA, Pignon JP, Graziano S, Douillard JY, Brambilla E, Le Chevalier T, Seymour L, Bourredjem A, Le Teuff G, Pirker R, Filipits M, Rosell R, Kratzke R, Bandarchi B, Ma X, Capelletti M, Soria JC, Tsao MS, Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy, J. Clin. Oncol. 31 (17) (2013) 2173–2181. - PMC - PubMed
    1. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, Trunzer K, Cappuzzo F, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J. Clin. Oncol. 29 (31) (2011) 4113–4120. - PubMed
    1. Pan W, Yang Y, Zhu H, Zhang Y, Zhou R, Sun X, KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: a meta-analysis of 41 studies, Oncotarget 7 (7) (2016) 8373–8388. - PMC - PubMed

Publication types

MeSH terms